

#### Dear Author,

Here are the proofs of your article.

- You can submit your corrections online, via e-mail or by fax.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and email the annotated PDF.
- For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- Check the questions that may have arisen during copy editing and insert your answers/ corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections within 48 hours, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

#### Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL: http://dx.doi.org/[DOI].

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information go to: <u>http://www.link.springer.com</u>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us if you would like to have these documents returned.

# Metadata of the article that will be visualized in OnlineFirst

ArticleTitle	A mathematical metho	d for parameter estimation in a tumor growth model			
Article Sub-Title					
Article CopyRight	SBMAC - Sociedade E	Brasileira de Matemática Aplicada e Computacional			
17 0	(This will be the copyright line in the final PDF)				
Journal Name	Computational and Ap	plied Mathematics			
Corresponding Author	Family Name	Fernández			
	Particle				
	Given Name	D.			
	Suffix				
	Division	Facultad de Matemática, Astronomía y Física			
	Organization	Universidad Nacional de Córdoba, CIEM-CONICET			
	Address	Medina Allende s/n, Ciudad Universitaria, 5000, Córdoba, Argentina			
	Email	dfernandez@famaf.unc.edu.ar			
Author	Family Name	Knopoff			
	Particle				
	Given Name	D.			
	Suffix				
	Division	Dipartimento di Scienze Matematiche			
	Organization	Politecnico di Torino			
	Address	Corso Duca degli Abruzzi 24, 10100, Torino, Italia			
	Division	Facultad de Matemática, Astronomía y Física			
	Organization	Universidad Nacional de Córdoba, CIEM-CONICET			
	Address	Medina Allende s/n, Ciudad Universitaria, 5000, Córdoba, Argentina			
	Email	knopoff@famaf.unc.edu.ar			
Author	Family Name	Torres			
	Particle				
	Given Name	G.			
	Suffix				
	Division	Facultad de Matemática, Astronomía y Física			
	Organization	Universidad Nacional de Córdoba, CIEM-CONICET			
	Address	Medina Allende s/n, Ciudad Universitaria, 5000, Córdoba, Argentina			
	Email	torres@famaf.unc.edu.ar			
Author	Family Name	Turner			
	Particle				
	Given Name	С.			
	Suffix				
	Division	Facultad de Matemática, Astronomía y Física			
	Organization	Universidad Nacional de Córdoba, CIEM-CONICET			
	Address	Medina Allende s/n, Ciudad Universitaria, 5000, Córdoba, Argentina			

	Email	turner@famaf.unc.edu.ar		
	Received	10 December 2013		
Schedule	Revised	20 April 2015		
	Accepted	7 July 2015		
Abstract	In this paper, we present a methodology for estimating the effectiveness of a drug, an unknown paramethat appears on an avascular, spheric tumor growth model formulated in terms of a coupled system of partial differential equations (PDEs). This model is formulated considering a continuum of live cells the grow by the action of a nutrient. Volume changes occur due to cell birth and death, describing a velocit field. The model assumes that when the drug is applied externally, it diffuses and kills cells. The effectiveness of the drug is obtained by solving an inverse problem which is a PDE-constrained optimization problem. We define suitable objective functions by fitting the modeled and the observed tumor radius and the inverse problem is solved numerically using a Pattern Search method. It is observed that the effectiveness of the drug is retrieved with a reasonable accuracy. Experiments with noised data			
Keywords (separated by '-')	Avascular tumor - PDE-const	trained optimization - Inverse problem - Mathematical modeling		
Mathematics Subject Classification (separated by '-')	35R30 - 65M32 - 35Q80			
Footnote Information	Communicated by George S. This work has been partially HEALTH-F4-2008-202047-F	Dulikravich. supported by the European Union FP7 Health Research Grant No. FP7- RESOLVE, and ANPCyT, CONICET and SECyT-UNC.		



## A mathematical method for parameter estimation in a tumor growth model

D. Knopoff<sup>1,2</sup> · D. Fernández<sup>2</sup> · G. Torres<sup>2</sup> · C. Turner<sup>2</sup>

Received: 10 December 2013 / Revised: 20 April 2015 / Accepted: 7 July 2015 © SBMAC - Sociedade Brasileira de Matemática Aplicada e Computacional 2015

- Abstract In this paper, we present a methodology for estimating the effectiveness of a drug,
- 2 an unknown parameter that appears on an avascular, spheric tumor growth model formulated
- <sup>3</sup> in terms of a coupled system of partial differential equations (PDEs). This model is formulated
- 4 considering a continuum of live cells that grow by the action of a nutrient. Volume changes
- 5 occur due to cell birth and death, describing a velocity field. The model assumes that when
- <sup>6</sup> the drug is applied externally, it diffuses and kills cells. The effectiveness of the drug is
- 7 obtained by solving an inverse problem which is a PDE-constrained optimization problem.
- 8 We define suitable objective functions by fitting the modeled and the observed tumor radius
- <sup>9</sup> and the inverse problem is solved numerically using a Pattern Search method. It is observed
- that the effectiveness of the drug is retrieved with a reasonable accuracy. Experiments with noised data are also considered and the results are compared and contrasted.

Communicated by George S. Dulikravich.

This work has been partially supported by the European Union FP7 Health Research Grant No. FP7-HEALTH-F4-2008-202047-RESOLVE, and ANPCyT, CONICET and SECyT-UNC.

D. Fernández dfernandez@famaf.unc.edu.ar

> D. Knopoff knopoff@famaf.unc.edu.ar

G. Torres torres@famaf.unc.edu.ar

C. Turner turner@famaf.unc.edu.ar

- <sup>1</sup> Dipartimento di Scienze Matematiche, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10100 Torino, Italia
- <sup>2</sup> Facultad de Matemática, Astronomía y Física, Universidad Nacional de Córdoba, CIEM-CONICET, Medina Allende s/n, Ciudad Universitaria, 5000 Córdoba, Argentina

Deringer Springer

<sup>12</sup> Keywords Avascular tumor  $\cdot$  PDE-constrained optimization  $\cdot$  Inverse problem  $\cdot$ 

13 Mathematical modeling

14 Mathematics Subject Classification 35R30 · 65M32 · 35Q80

#### 1 Introduction

The scientific community agrees that mathematical modeling of tumor growth is an effec-16 tive and important step in promoting knowledge about cancer, becoming one of the most 17 studied topics in mathematical biology. Pioneer models for tumor growth were proposed 18 by Adam (1986) and Greenspan (1972). Some developments in the last years include, 19 among many others, cell-focused (Rejniak and McCawley 2010), hybrid (Preziosi and 20 Vitale 2011) and continuum models (Wise et al. 2008), each of them with some spe-21 cific fields of applications. In (Byrne and Drasdo 2009), a comparison between them is 22 considered. Some important contributions in the field include models based on the diffu-23 sion of nutrients taking into account the physiological changes accompanying the growth 24 of avascular tumors (Kiran et al. 2009), those regarding to biological motivations for in 25 silico models of cancer (Edelman et al. 2010), multi-phase models regarding thermody-26 namic equilibrium (Grillo et al. 2009), and the recent Bayesian approach for selecting 27 and validating mathematical and computational models (Oden et al. 2013). The recent 28 papers (Bellomo et al. 2008; Tracqui 2009; Lowengrub et al. 2010; Roose et al. 2007) are 29 valuable reviews and the interested reader is referred to them for additional useful refer-30 ences. 31

The advantages of continuum models are that they are understandable, tractable to mathematical analysis and intuitive from biological principles. They contain a few parameters and can use laws from physics. On the other hand, the advantages of discrete models are able to work in other scales and each cell can be treated independently with no extra complication (Roose et al. 2007).

In this present paper, we focus on the growth of a multicellular spheroid (MCS) (Hamilton 1998). A MCS is a cluster of cancer cells grown in vitro to mimic the early stages of in vivo avascular tumor growth. In fact, in vitro observations (Sutherland 1988) suggest that in the early stages solid tumors remain approximately spherical as they grow, possessing a central core of necrotic cells, with proliferating cells restricted to the outer rim of the tumor.

Since this model considers the evolution of a system from a single progenitor cell to  $\mathcal{O}(10^6)$  cells in vitro, the continuum approach is better than an agent-based approach (Byrne and Drasdo 2009).

Mathematical models of MCSs are typically continuous models which consist of an ordi-45 nary differential equation (ODE) representing the evolution of the outer tumor boundary, and 46 a set of partial differential equations (PDEs) describing, for example, the distribution within 47 the tumor of vital nutrients, such as oxygen and glucose, and growth inhibitors (Byrne and 48 Chaplain 1997). That is why in this general approach of modeling, the key variables are the 49 tumor size, e.g., tumor radius, and the concentration of the aforementioned substances. Since 50 the tumor changes in size over time, the domain on which the models are formulated must be 51 determined as part of the solution process, giving a vast class of moving boundary problems 52 (Byrne and Chaplain 1997; Crank 1984). 53

In this article, we propose a framework for estimating an unknown parameter via PDEconstrained optimization, following a model by Ward and King (2003), which is a two-phase

<sup>56</sup> model with the two phases being live cells and dead cells.



In this approach, avascular tumor growth is modeled via a coupled nonlinear system of PDEs, making its numerical solution quite challenging. It is worth mentioning that all tumor growth models involve a certain number of parameters (Hogea et al. 2008), and that some of them are difficult to obtain experimentally. In particular, we will consider a parameter that represents the effectiveness of a chemotherapeutic drug, because it encapsulates both the drug degradation rate and the diffusivity, and it is consequently a key parameter in determining the success of the drug (Ward and King 2003). In addition, according to the definition given 63 in (Ward and King 2003), the drug penetration depth within the tumor can be shown to be proportional to the square root of this parameter.

To obtain the effectiveness of the drug, we define a function to be minimized that estab-66 lishes a comparison between the measured radius of the tumor and the one predicted by 67 the model. We observe that the evolution of the radius of the MCSs is in fact a measurable 68 variable. For instance, in (Monazzam et al. 2007; Bergstrom et al. 2008; Herrmann et al. 69 2008), special procedures were used to evaluate tumor growth and quantify its radius. 70

This kind of problem constitutes a particular application of the so-called inverse problems, 71 which are being increasingly used in a broad number of fields in applied sciences. For 72 instance, problems referred to structured population dynamics (Perthame and Zubelli 2007), 73 computerized tomography and image reconstruction in medical imaging (van den Doel et al. 74 2011; Zubelli et al. 2003), and more specifically tumor growth (Knopoff et al. 2013; Agnelli 75 et al. 2011; Hogea et al. 2008), among many others. An inverse problem assumes a direct 76 problem that is a well-posed problem of mathematical physics. In other words, if we know 77 completely a physical model, we have a classical mathematical description of it. But if one of 78 the parameters describing this model is to be found (from additional boundary/experimental 79 data), then we arrive at an inverse problem. 80

The paper is organized as follows. Section 2 introduces the avascular tumor growth model. 81 Section 3 presents a numerical scheme for solving the system of PDEs. Section 4 formulates 82 the inverse problem, defining the functions to be minimized. Section 5 is dedicated to the 83 numerical experiments and the discussion of the results. Finally, conclusions are given in 84 Sect. 6. 85

#### 2 Mathematical model 86

We consider the model proposed by (Ward and King 2003). The tumor is a spheroid which 87 consists of a continuum of living cells, in one of two states: live or dead. The birth and death 88 rates depend on the nutrient and chemotherapeutic drug concentrations. It is supposed that 89 those processes generate volume changes, leading to cell movement described by a velocity 90 field. Assuming spherical symmetry, the system of equations to be studied is: 91

93

94

95

$$\frac{\partial n}{\partial \tau} + \frac{1}{r^2} \frac{\partial (r^2 v n)}{\partial r} = [k_m(c) - k_d(c) - KG(k_m(c))w]n, \tag{1}$$

$$\frac{\partial c}{\partial \tau} + \frac{1}{r^2} \frac{\partial (r^2 vc)}{\partial r} = \frac{D}{r^2} \frac{\partial}{\partial r} \left( r^2 \frac{\partial c}{\partial r} \right) - \beta k_m(c)n, \tag{2}$$

$$\frac{1}{r^2} \frac{\partial (r^2 v)}{\partial r} = [V_{\rm L} k_m(c) - (V_{\rm L} - V_{\rm D}) \{k_d(c) + K G(k_m(c))w\}]n, \qquad (3)$$

$$\frac{\partial w}{\partial \tau} + \frac{1}{r^2} \frac{\partial (r^2 v w)}{\partial r} = \frac{D_w}{r^2} \frac{\partial}{\partial r} \left( r^2 \frac{\partial w}{\partial r} \right) - \frac{K}{\omega} G(k_m(c)) w n, \tag{4}$$

D Springer

57

58

59

60

61

62

64

Variable	Dimensionless variable	Description		
r	у	Spatial independent variable		
τ	t	Temporal independent variable		
n	Ν	Live cell density		
с	С	Nutrient concentration		
υ	V	Velocity field		
w	W	Drug concentration		
S	S	Tumor radius		

 Table 1
 Summary of model variables and symbols

where the independent variables are the radial position r inside the tumor and time  $\tau$  and 96 the dependent variables n, c, v and w are the live cell density (cells/unit volume), nutrient 97 concentration, velocity and drug concentration, respectively. A summary of model variables 98 is included in Table 1 at the end of this Section. As it is described in (Ward and King 2003), 99 Eq. (1) states that the rate of change of n is dependent on the difference between the birth 100 rate  $k_m(c)$ , and the death rate, which can be either natural at a rate  $k_d(c)$  [as described in 101 (Ward and King 1997)] or due to drug effects, at a rate  $KG(k_m(c))w$ . The functions  $k_m$  and 102  $k_d$  are taken to be generalized Michaelis–Menten kinetics with exponent 1, i.e., 103

$$k_m(c) = A\left(\frac{c}{c_c + c}\right), \quad k_d(c) = B\left(1 - \sigma \frac{c}{c_d + c}\right). \tag{5}$$

where *A* and *B* are the maximum birth and death rates theoretically attainable when *c* tends to infinity and c = 0, respectively, the constants  $c_c$  and  $c_d$  are the standard half-saturation concentrations in the Michaelis–Menten terms, and  $B(1 - \sigma)$  is the minimum death rate attainable when the concentration tends to infinity with  $0 \le \sigma \le 1$ . The constant *K* is the maximum possible rate of drug-induced cell death and *G* is a function that represents the dependence between drug action and cell cycle.

Equation (2) states that the nutrient is consumed at a rate proportional (with constant of proportionality equal to  $\beta$ ) to the rate of mitosis, and its diffusion is described by the Fick's law with the diffusion coefficient *D* taken to be constant since spheroid's heterogeneity does not significantly affect diffusion rates.

Equation (3) states that the rate of volume change is given by the difference in volume generated via birth from that lost by death (it is assumed that a live cell occupies a volume  $V_L$  that is twice the volume of a death cell  $V_D$ ).

The diffusion of the drug is also described by Fick's law (with diffusion coefficient  $D_w$ ), and it is assumed that it is degraded only when it attacks a living cell, giving a maximum degradation rate  $K/\omega$ . The constant  $\omega$  can be interpreted as a measure of the drug's effectiveness, as explained in (Ward and King 2003), with increasing  $\omega$  implying that less drug is consumed to produce the same effects during the killing process. These considerations lead to Eq. (4). An important consequence of knowing  $\omega$  is that it let us compute the drug penetration depth  $\sqrt{\omega D_w V_L/K}$ .

Since the tumor radius changes over time, the domain on which the model is formulated must be determined as part of the solution. Let  $s(\tau)$  be the tumor radius at time  $\tau$ . Let us suppose that at time  $\tau = 0$  the tumor has a radius  $s_I$  and a living cell density  $n_I(r)$ . The initial conditions on *c* and *w* are not necessary under the quasi-steady assumptions. Then

104

Journal: 40314 Article No.: 0259 TYPESET DISK LE CP Disp.:2015/7/16 Pages: 16 Layout: Small



129

132

$$n(r, 0) = n_I(r), \quad s(0) = s_I.$$
 (6)

For the boundary conditions, we suppose that there is no flux about r = 0 due to symmetry. The boundary conditions are:

$$\frac{\partial c}{\partial r}(0,\tau) = 0, \quad c(s(\tau),\tau) = c_0, 
v(0,\tau) = 0, \quad v(s(\tau),\tau) = s'(\tau), 
\frac{\partial w}{\partial r}(0,\tau) = 0, \quad w(s(\tau),\tau) = w_0(\tau),$$
(7)

where  $c_0$  and  $w_0(\tau)$  are external nutrient and drug concentrations, respectively.

The function  $w_0(\tau)$  depends on the chemotherapy protocol, which describes the schedule of tests, dosages and the length of the study. For example, we can take different options for drug administration as shown in Fig. 1. Protocols 3 and 4 represent single and multiple doses like in (Ward and King 2003), protocols 1 and 2 represent single and multiple doses that could simulate a more realistic evolution of the external drug concentration.

Following the ideas in (Adam 1986; Byrne and Chaplain 1997; Ward and King 1997, 2003), we rescale the mathematical model and transform the spatial domain  $[0, s(\tau)]$  of the

D Springer JDMAC

tumor into the dimensionless spatial interval [0, 1]. Similarly, we will define the dimensionless 141

time t as  $\tau A$ , where the rate A was defined above. This is a very useful approach when dealing 142 with free boundary problems, as mentioned in (Crank 1984). Hence, let us define the following 143 functions 144

$$N(y,t) = V_{\rm L}n(ys(t/A), t/A),$$

$$C(y,t) = \frac{1}{c_0} c(ys(t/A), t/A),$$
  
$$V(y,t) = \frac{1}{Ar_0} v(ys(t/A), t/A),$$

147 148

145

146

Author Proof

$$W(y,t) = \frac{1}{W_0} w(ys(t/A), t/A)$$
$$S(t) = \frac{1}{r_0} s(t/A),$$

(10)

149

where  $W_0$  is a suitable reference drug concentration and  $r_0 = (3V_L/(4\pi))^{1/3}$  is the radius of 150 a single live cell. 151

Notice that if we apply the change of variables (8) to Eqs. (2) and (4), then 152

$$\nu \left[ C_t - \frac{S'}{S} y C_y + \frac{2V}{yS} C + \frac{(VC)_y}{S} \right] = \frac{1}{S^2} \left( C_{yy} + \frac{2}{y} C_y \right) - \widehat{\beta} \, \widehat{k}_m(C) N, \qquad (9)$$

$$\chi \left[ W_t - \frac{S'}{S} y W_y + \frac{2V}{yS} W + \frac{(VW)_y}{S} \right] = \frac{1}{S^2} \left( W_{yy} + \frac{2}{y} W_y \right)$$

$$- \frac{\widehat{k}}{\alpha} G \left( A \, \widehat{k}_m(C) \right) W N, \qquad (10)$$

155

154

where 156

157

$$\widehat{k}_m(C) = \frac{C}{\widehat{c}_c + C},$$

and  $v = Ar_0^2/D$ ,  $\chi = Ar_0^2/D_w$ ,  $\hat{c}_c = c_c/c_0$ ,  $\hat{\beta} = Ar_0^2\beta/(V_L c_0 D)$ ,  $\hat{K} = KW_0/A$  and  $\alpha = \omega D_w W_0 V_0/(Ar_0^2)$ 158  $\alpha = \omega D_w W_0 V_{\rm L} / (A r_0^2).$ 159

The dimensionless numbers  $\nu$  and  $\chi$  can be interpreted as the ratio of two timescales, 160 namely, the tumor growth  $(1/A \approx 1 \text{ day})$  and the much shorter nutrient and drug diffusions 161  $(r_0^2/D, r_0^2/D_w \approx 1 \text{ min})$ . Therefore,  $\nu$  and  $\chi$  are approximately  $10^{-5}$ . That is why we adopt 162 a quasi-steady assumption in the nutrient and drug equations [see Ward and King (1997)]. 163

Then, the system of Eqs. (1)-(4), taking into account the above comments on Eqs. (9) and 164 (10), can be written in its nondimensional form as 165

$$N_t - \frac{S'}{S}yN_y + \frac{V}{S}N_y = [a(C, W) - b(C, W)N]N,$$
(11)

$$C_{yy} + \frac{2}{y}C_y = \widehat{\beta}\,\widehat{k}_m(C)S^2N,\tag{12}$$

$$V_y + \frac{2}{y}V = b(C, W)SN,$$
(13)

$$W_{yy} + \frac{2}{y}W_y = \frac{\widehat{K}}{\alpha}G(A\widehat{k}_m(C))S^2NW,$$
(14)

169

166

167

168



💢 Journal: 40314 Article No.: 0259 🗌 TYPESET 🗌 DISK 🗌 LE 🗌 CP Disp.: 2015/7/16 Pages: 16 Layout: Small

170 for 0 < y < 1 and t > 0, where

$$\widehat{k}_d(C, W) = \frac{B}{A} \left( 1 - \sigma \frac{C}{\widehat{c}_d + C} \right) + \widehat{K} G(A \widehat{k}_m(C)) W,$$
$$a(C, W) = \widehat{k}_m(C) - \widehat{k}_d(C, W),$$

$$b(C, W) = \widehat{k}_m(C) - (1 - \delta)\widehat{k}_d(C, W),$$

and  $\hat{c}_d = c_d/c_0$  and  $\delta = V_D/V_L$ . The initial and boundary conditions (6)–(7) become:

$$N(y,0) = N_I(y) := V_L n(ys_I,0), \qquad S(0) = \frac{1}{r_0} s_I, \tag{15}$$

177 and

178

176

$$C_{y}(0,t) = 0, \quad C(1,t) = 1,$$
  

$$V(0,t) = 0, \quad V(1,t) = S'(t),$$
  

$$W_{y}(0,t) = 0, \quad W(1,t) = \frac{1}{W_{0}}w_{0}(t/A),$$
  
(16)

<sup>179</sup> From now on, Eqs. (11)–(16) will be referred to as the direct problem.

#### **3 Solving the direct problem**

<sup>181</sup> In this section, we will present a numerical scheme for solving the system of Eqs. (11)–(16).

Let *n* and *m* be positive integers, T > 0 a given final time and consider a uniform space and time discretization:  $y_i = i\Delta y$ ,  $t_j = j\Delta t$ , for i = 0, ..., n, and j = 0, ..., m. Then, we must determine the functional values  $N_{ij}$ ,  $C_{ij}$ ,  $V_{ij}$ ,  $W_{ij}$  and  $S_j$  satisfying:

186

$$\frac{N_{i,j+1} - N_{ij}}{\Delta t} - \frac{V_{nj}y_i - V_{ij}}{S_j} \frac{N_{i+1,j} - N_{ij}}{\Delta y} = \left[a(C_{ij}, W_{ij}) - b(C_{ij}, W_{ij})N_{ij}\right]N_{ij},$$
(17)

$$\frac{C_{i+1,j} - 2C_{ij} + C_{i-1,j}}{(\Delta y)^2} + \frac{2}{v_i} \frac{C_{i+1,j} - C_{i-1,j}}{2\Delta y} = \widehat{\beta} \, \widehat{k}_m(C_{ij}) S_j^2 N_{ij}, \tag{18}$$

189

190

$$\frac{W_{i+1,j} - 2W_{ij} + W_{i-1,j}}{(\Delta y)^2} + \frac{2}{y_i} \frac{W_{i+1,j} - W_{i-1,j}}{2\Delta y} = \frac{\widehat{K}}{\alpha} G(A\widehat{k}_m(C_{ij}))S_j^2 N_{ij} W_{ij}, \quad (20)$$

197

$$\frac{S_{j+1} - S_j}{\Delta t} = V_{nj}.$$
(21)

 $-\frac{V_{ij}}{V_{ij}} + \frac{2}{-}V_{ij} = b(C_{ij}, W_{ij})S_j N_{ij},$ 

Assuming that functions N, C, V, W, and S are sufficiently smooth, we can avoid the singularity of (12)–(14) at y = 0. Notice that  $C_y(0, t) = 0$  [by (16)] implies  $C_y(y, t)/y \rightarrow$  $C_{yy}(0, t)$  when  $y \rightarrow 0$ . Analogously, for V and W, we obtain

195 
$$3C_{yy}(0,t) = \widehat{\beta} \, \widehat{k}_m(C(0,t)) S(t)^2 N(0,t),$$

196 
$$3V_{y}(0,t) = b(C(0,t), W(0,t))S(t)N(0,t),$$

$$3W_{yy}(0,t) = \frac{\widehat{K}}{\alpha} G(A\widehat{k}_m(C(0,t)))S(t)^2 N(0,t)W(0,t).$$

Deringer

(19)

Journal: 40314 Article No.: 0259 TYPESET DISK LE CP Disp.:2015/7/16 Pages: 16 Layout: Small

Discretizing the above equations, we have

$$6\frac{C_{1j} - C_{0j}}{(\Delta y)^2} = \widehat{\beta}\,\widehat{k}_m(C_{0j})S_j^2 N_{0j},\tag{22}$$

$$6\frac{W_{1j} - W_{0j}}{(\Delta y)^2} = \frac{\widehat{K}}{\alpha} G(A\widehat{k}_m(C_{0j})) S_j^2 N_{0j} W_{0j},$$
(23)

$$3\frac{V_{1j}}{\Delta y} = b(C_{0j}, W_{0j})S_j N_{0j},$$
(24)

where we used a central difference on space at the boundary y = 0 to obtain  $C_{yy}(0, t_j) \approx 2(C_{1j} - C_{0j})/(\Delta y)^2$  (similarly for variables *W* and *V*).

On the other hand, by Eq. (17) and using the fact that  $y_n = 1$  and  $C_{nj} = 1$  for all j, we get

$$\frac{N_{n,j+1} - N_{nj}}{\Delta t} = [a(1, W_{nj}) - b(1, W_{nj})N_{nj}]N_{nj},$$
(25)

The procedure for solving the discretized Eqs. (17)–(25) is the following.

#### 208 Algorithm 1

- <sup>209</sup> 1. Set j = 0. <sup>210</sup> 2. If j = 0 set  $N_{i0} = N_I(y_i)$  for i = 0, ..., n, and  $S_0 = s_I/r_0$ , otherwise
- 211 Define  $N_{ni}$  satisfying Eq. (25).
- <sup>212</sup> Define  $N_{ij}$ , i = 0, ..., n 1 satisfying (17).

$$- Define S_i satisfying (21).$$

3. Set  $C_{nj} = 1$  and find  $C_{ij}$ , i = 0, ..., n - 1 solving the nonlinear system (18) and (22).

4. Set  $W_{nj} = w_0(t_j)/W_0$  and find  $W_{ij}$ , i = 0, ..., n-1 solving the linear system (20) and (23).

5. Set  $V_{0j} = 0$  and find  $V_{ij}$ , i = 1, ..., n solving the linear system (19) and (24).

218 6. Set j = j + 1 and return to step 2.

To verify the numerical procedure, we solved the direct problem (11)–(16) associated to a real tumor. Let us consider V79 spheroids growing in glucose supply conditions. This cell line, which was developed from lung tissue of a young male Chinese hamster, has a high plating efficiency (80%), and a generation time of 12–14 h. The line was renamed V79 by Elkind in 1958 (Ford et al. 1958).

According to (Hlatky et al. 1988; Ward and King 1997, 2003) and references therein, the corresponding parameters are:  $c_c = 1.4 \times 10^{-4} \text{ g/cm}^3$ ,  $c_d = 7 \times 10^{-5} \text{ g/cm}^3$ , A = B = $1.98 \times 10^{-5} \text{ l/s}$ ,  $\sigma = 0.9$ ,  $K = 661.39 \text{ cm}^3/(\text{gs})$ ,  $D = 1.1 \times 10^{-6} \text{ cm}^2/\text{s}$ ,  $\beta = 1.01 \times 10^{-9}$ g/cell,  $V_L = 10^{-9} \text{ cm}^3$ ,  $V_D = 5 \times 10^{-10} \text{ cm}^3$ ,  $D_w = 5.5 \times 10^{-6} \text{ cm}^2/\text{s}$  and  $c_0 = 1.4 \times 10^{-3}$ g/cm<sup>3</sup>. Consequently, the dimensionless parameters corresponding to the direct problem are:  $\hat{c}_c = 0.1$ ,  $\hat{c}_d = 0.05$ ,  $\hat{K} = 50$ ,  $\hat{\beta} = 0.005$ ,  $\delta = 0.5$ . We assume a linear dependence between drug action and cell cycle, that is,  $G(k_m(c)) = k_m(c)/A$  (Ward and King 2003).

If we first consider the tumor growth without the action of the drug, beginning from a single cell, we can see that the evolution of the radius is linear with respect to time for large times (see Fig. 2a). In Fig. 2b, we also show the evolution of the live cell density and the growth of the necrotic core. Thus, the resolution of the proposed numerical scheme, removing the action of the drug, is compatible with the results presented in (Ward and King 1997, Figs. 1, 2).

Now, let the tumor evolve without the action of the drug from a dimensionless time equal to -25 (corresponding to 350h) obtaining a tumor size of S(0) = 141.87 (corresponding

198

199

200

201

206

207

21:

😧 Journal: 40314 Article No.: 0259 🗌 TYPESET 🗋 DISK 🗌 LE 🗌 CP Disp.: 2015/7/16 Pages: 16 Layout: Small



Fig. 2 a, b show the evolution of the tumor radius and the live cell density without the action of drug. c shows the evolution of the tumor radius under a chemotherapy treatment for several values of  $\alpha$ . d Velocity at the tumor's boundary for a fixed dimensionless time (t = 0.2) for different values of  $\alpha$ 

to 880.9  $\mu$ m) and an initial live cell density  $N_I(y)$ . From that moment, we apply a protocol consisting of a 28 h exposure to a constant drug concentration  $w_0(\tau) = 1.5 \,\mu$ g/ml,  $0 \le \tau \le$ 28. We solved the direct problem for several values of the parameter  $\alpha$  as shown in Fig. 2c obtaining results similar to those in (Ward and King 2003, Fig. 2). From Fig. 2c, we can see that the parameter  $\alpha$  can be regarded as the dimensionless effectiveness of the drug since for greater values of  $\alpha$  the tumor becomes smaller (see the definition of  $\alpha$ ).

An interesting question to answer is: for which value of  $\alpha$  can be stated that tumor will decrease in size? To determine this value, we take into account the velocity in the boundary at a fixed time for different values of  $\alpha$ . For example, in Fig. 2d, we can see that if we fix the dimensionless time t = 0.2, the function V(1, t) has a root in  $\alpha \approx 58$ .

#### **4 Inverse problem**

As it was mentioned before, some of the parameters that describe the mathematical model are unknown, for example,  $c_c$ ,  $c_d$ , A, B,  $\sigma$ ,  $\omega$ , among others. However, for parameters related to the model without the action of the drug (Ward and King 1997), it is not necessary to

Deringer Springer

consider the model described in (Ward and King 2003). For a methodology for estimating those parameters, we refer to (Knopoff et al. 2013). In this work, we focused on the recovery of the parameter  $\alpha$  since it appears exclusively in the model with drug and it represents its dimensionless effectiveness. Moreover, it can be shown that the drug penetration depth is equal to  $r_0(\alpha/\hat{K})^{1/2}$ . For this purpose, we formulate the following problem:

### Find a parameter value $\alpha^*$ able to generate data that best match the available information over time $0 \le t \le T$ .

Since the direct problem can be solved for each value of  $\alpha > 0$ , we should construct an objective function  $\mathcal{J}$  which gives us some *distance* between the experimental (real) data and the solution of the direct problem for each value of  $\alpha$ . Thus, the inverse problem can be formulated as:

Find  $\alpha^* > 0$  such that  $\mathcal{J}(\alpha^*) \le \mathcal{J}(\alpha)$  for all  $\alpha > 0$ , (26)

265 or equivalently

$$\alpha^* = \operatorname*{argmin}_{\alpha > 0} \mathcal{J}(\alpha). \tag{27}$$

To define a suitable objective function  $\mathcal{J}$ , it is important to decide which variables could be measured experimentally, for instance, the tumor radius evolution. So, the first possibility for defining a function (associated to the dimensionless problem) could be

$$\mathcal{T}(\alpha) = \int_0^T \left( S_\alpha(t) - S^*(t) \right)^2 \mathrm{d}t, \qquad (28)$$

where  $S_{\alpha}(t)$  is the dimensionless radius at time *t* obtained by solving the direct problem for a certain value of  $\alpha$ , and  $S^*(t)$  is a function that is obtained (e.g., by interpolation) from experimental measurements of the the tumor radius at certain times.

Motivated by the considerations stated in (Ward and King 2003, pp. 194–196) based on (Sano et al. 1984): "...there is very little difference in cell survival, at the time the final treatment ends, between a single dose of the drug or the same amount of drug applied in multiple doses", we define a function representing the mean external drug concentration over the duration of the experiment, namely:

279

$$\mathcal{I}(w_o) = \frac{1}{\tilde{\tau}} \int_0^{\tilde{\tau}} w_o(\tau) \mathrm{d}\tau, \qquad (29)$$

where  $\tilde{\tau}$  is the dimensional final time ( $\tilde{\tau} = T/A$ ). Note that  $\mathcal{I}$  is a quantity that depends on the drug administration protocol and that it has units corresponding to concentration.

The four protocols shown in Fig. 1 were selected in such a way that the quantity  $\mathcal{I}$  is conserved for all of them. From Fig. 3, we observe that after drug treatment with these protocols, the spheroids recover to grow at comparable sizes.

Thus, it is reasonable to consider an objective function that takes into account only the tumor radius at final time, that is

287

292

1

$$\mathcal{J}(\alpha) = \left(S_{\alpha}(T) - S^{*}(T)\right)^{2}.$$
(30)

where  $S_{\alpha}$  can be obtained from any protocol with the same  $\mathcal{I}$  associated to the protocol used to obtain the data  $S^*$ .

Finally, if it were possible to have measurements of the live cell density inside the tumor for certain times, we could define:

$$\mathcal{J}(\alpha) = \mu \int_0^1 \int_0^T \left( N_\alpha(y, t) - N^*(y, t) \right)^2 dt dy + \int_0^T \left( S_\alpha(t) - S^*(t) \right)^2 dt, \qquad (31)$$

Deringer JUNC

😧 Journal: 40314 Article No.: 0259 🗌 TYPESET 🗋 DISK 🗌 LE 🗌 CP Disp.: 2015/7/16 Pages: 16 Layout: Small

258

259

264

266



Fig. 3 Evolution of the tumor radius for different treatment protocols: **a** blue for protocol 1, **b** green for protocol 2, **c** red for protocol 3 and **d** cyan for protocol 4

where  $N_{\alpha}$  is the dimensionless live cell density obtained by solving the direct problem for a certain value of  $\alpha$ ,  $N^*$  is a function that is obtained (e.g., by interpolation) from experimental measurements of the the live cell density, and  $\mu$  is a scaling parameter. Notice that when  $\mu = 0$ , we recover the objective function as in (28).

We have defined the objective functions in terms of variables that can be experimentally measured as explained in Knopoff et al. (2013). For example, the density of living cells could be measured via biomedical imaging like PET technique for a tumor in vivo, or via immunofluorescence and electronic scan microscopy technique for in vitro cases (Taylor et al. 1986; Martin et al. 1994). In addition, in (Freyer et al. 1986), the mean size of a spheroid population was determined by measuring two orthogonal diameters on spheroids using an

Deringer

Advantages and disadvantages of each objective function will become clear later.

#### **5 Numerical experiments**

To solve the inverse problem (26), we used a Pattern Search method (Torczon 1997; Dolan et al. 2003; Audet and Dennis 2002). This method is a very effective numerical optimization method for engineering problems where the computation of the derivative of the objective function is expensive. In particular, it belongs to the family of derivative-free methods.

Pattern Search methods proceed by conducting a series of exploratory moves about the current iterate before identifying a new iterate. These moves can be viewed as a search about the current iterate for a trial point with a lower function value. At each iteration, the algorithm reduces the step size if the exploratory moves algorithm fails to produce a trial step that gives a simple decrease. If the exploratory moves algorithm does produce a trial step that gives simple decrease, then this algorithm either increases the step size or preserves the current step size. An implementation of this method can be found in (Venkataraman 2009).

The numerical experiments were run in Matlab R2011a in a PC running Linux OS, Intel 321 Core i5. The direct problem was solved according to Algorithm 1 with parameters m =322 800, n = 500, T = 4; initial conditions  $S_0$  and  $N_I$  were obtained after letting the tumor 323 evolve without the action of the drug from a dimensionless time equal to -25; physical 324 constants correspond to a V79 spheroid growing in glucose supply conditions. The inverse 325 problem was solved using the Matlab built-in function patternsearch with an initial 326 point randomly chosen in the interval  $[0, 10^6]$ . Function (28) was computed employing the 327 composite trapezoidal rule with temporal discretization taken as in the direct problem. The 328 function  $S_{\alpha}$  in (30) was calculated using protocol 3 for all the experiments. 329

Consider first the optimization problem (26) that consists of minimizing the functions (28) 330 or (30), where  $S^*$  is generated by solving the direct problem using Algorithm 1, for certain 331 choices of the model parameter  $\alpha = \alpha^*$ , where  $\alpha^* = 17.3$ ,  $\alpha^* = 314.0$  and  $\alpha^* = 5350.1$ , 332 to represent different orders of magnitude that this parameter can attain. We perform these 333 simulations for the four protocols shown in Fig. 1. Then, to study the stability of the proposed 334 procedure, we consider a tumor radius measurement affected with a random noise of  $\pm 5 \,\mu$ m 335 uniformly distributed, that for the considered spheroids corresponds to about 0.5% of the 336 tumor radius. The noise was generated using the Matlab built-in function rand. 337

We perform some experiments to investigate how close the original value of the parameter can be retrieved. We stress that the inverse problem is not trivial, because we do not know, for instance, if the optimization problem has a solution or, in that case, if it is unique or if the method converges to another local minima. However, according to Fig. 4, the shape of the objective functions indicates that the inverse problem (26) has a unique solution.

Tables 2, 3, 4 and 5 show the solution of the inverse problem for certain protocols and certain values of  $\alpha^*$ .

On one hand, according to Table 2, the estimated parameter  $\alpha$  is retrieved very well, with a percent error lower than 0.4 % in most cases, using the function (28) for every choice of  $\alpha^*$ . On the other hand, Table 3 shows that the parameter  $\alpha$  is retrieved quite well for large values



**Author Proof** 

308

Journal: 40314 Article No.: 0259 TYPESET DISK LE CP Disp.:2015/7/16 Pages: 16 Layout: Small



Fig. 4 Objective functions (28) and (30) for  $\mathbf{a} \alpha^* = 314$  and  $\mathbf{b} \alpha^* = 5350.1$ 

**Table 2** Estimated  $\alpha$  and percent error  $e_{\infty}$  with function (28) using generated data without noise

$\alpha^*$	Protocol 1		Protocol 2		Protocol 3		Protocol 4	
	$\alpha_{\rm est}$	е%						
17.3	17.23	0.39	17.27	0.17	17.81	2.97	16.53	4.48
314.0	313.24	0.24	313.60	0.13	314.58	0.18	314.54	0.17
5350.1	5349.12	0.02	5351.03	0.02	5349.24	0.02	5349.46	0.01

**Table 3** Estimated  $\alpha$  and percent error  $e_{\%}$  with function (28) using generated data with noise

α*	Protocol 1		Protocol 2		Protocol 3		Protocol 4	
	$\alpha_{\rm est}$	е%						
17.3	24.83	43.52	10.48	39.44	22.95	32.68	8.05	53.46
314.0	329.87	5.05	286.32	8.82	349.86	11.42	268.30	14.56
5350.1	5195.90	2.88	5374.20	0.45	5128.40	4.14	5198.70	2.83

**Table 4** Estimated  $\alpha$  and percent error  $e_{\%}$  with function (30) using generated data without noise

$\alpha^*$	Protocol 1		Protocol 2	Protocol 2		Protocol 3		Protocol 4	
	$\alpha_{\rm est}$	е%	α <sub>est</sub>	e%	$\alpha_{\rm est}$	е%	$\alpha_{\rm est}$	e‰	
17.3	15.92	7.98	17.27	0.19	18.05	4.32	13.24	23.49	
314.0	295.24	5.98	295.24	5.98	313.69	0.10	241.93	22.95	
5350.1	4918.20	8.07	4755.00	11.12	5349.60	0.01	3257.60	39.11	

of  $\alpha^*$ . To recover small values of  $\alpha^*$ , it is necessary to have more accurate measurements. Notice that in the experiments with and without noise, the percent error decreases as  $\alpha^*$ becomes greater.

Since we need to compute a good approximation of the integral in (28), it is necessary to have enough measurements to capture the tumor's evolution for a given protocol.

Deringer

$\alpha^*$	Protocol 1		Protocol 2		Protocol 3		Protocol 4	
	$\alpha_{\rm est}$	е%						
17.3	16.72	3.34	14.63	15.43	32.67	88.83	3.26	81.18
314.0	352.54	12.27	291.45	7.18	310.56	1.10	182.93	41.74
5350.1	4824.10	9.83	4981.00	6.90	5360.90	0.20	3280.70	38.68

**Table 5** Estimated  $\alpha$  and percent error  $e_{\%}$  with function (30) using generated data with noise

If it were not possible to have measurements of the tumor radius for several times, or if the 353 drug administration protocol were unknown, we could use the function (30) that requires only 354 a measurement at final time and an estimation of the mean external drug concentration value 355  $\mathcal{I}$  [see (29)]. It is observed that the results obtained using this function are, although worse 356 than those from function (28), still acceptable, given the limited information required. If this 357 information is affected with noise, then it will clearly be a source of errors, so more accurate 358 measurements are needed. Tables 4 and 5 show that, in general, the percent errors are around 359 10 % for protocols 1 and 2. Protocol 3 is remarkably good compared with the other protocols 360 in most cases, maybe due to the fact that the function  $S_{\alpha}$  in (30) was obtained precisely 361 with this protocol. Results in protocol 4 are not satisfactory at all, maybe due to an early 362 final observation time. For example, notice from Fig. 3 that the furthest curve corresponds to 363 protocol 4. This curve has not yet reached its stationary behavior, so a larger final time must 364 be considered. 365

#### 6 Conclusions and looking ahead 366

A methodology for the estimation of the drug effectiveness parameter, which is involved in the 367 growth of an avascular in vitro tumor with drug, has been presented in this paper. Basically, 368 we used the Pattern Search method to solve the inverse problem that can be regarded as 369 a PDE-constrained optimization problem, where the constraints are given by the coupled 370 system of PDEs proposed by Ward and King (2003). 371

Two objective functions were proposed to solve the inverse problem. The first one takes 372 into account the evolution of the tumor radius on time. It is worth stressing that the numerical 373 experiments performed with this function let us retrieve the parameter  $\alpha$  accurately, especially 374 for the cases in which no noise was added to the data. The counterpart is that the radius should 375 be monitored at various times and that the drug administration protocol should be known. The 376 second objective function only needs one measurement of the radius at a final time and the 377 knowledge of the mean external drug concentration during the simulation time. Of course, 378 the cost of using less information is that the parameter is retrieved with a higher, but still 379 acceptable, error. 380

There is considerable scope for further work and future research based on the approach 381 presented in this paper. For instance, an obvious extension is to consider a more complex 382 model for an in vitro tumor representing the vascularized case. The following step could be 383 to move on to the in vivo case where parameters are even more difficult to retrieve, either 384 by the intrinsic complexity of the model or by the lack of suitable measurements. The same 385 reasonings apply to the case of the growth of cancer cells under the surveillance of the 386 immune system, for instance in Bellouquid et al. (2013), a qualitative analysis is performed 387 but it would be worth retrieving the parameters accurately to validate the model. 388

Journal: 40314 Article No.: 0259 🔲 TYPESET 🔄 DISK 🔄 LE 🔄 CP Disp.:2015/7/16 Pages: 16 Layout: Small

Acknowledgments We thank the referees and the Editor for their careful reading of the manuscript and their
 valuable suggestions. This work was carried out with the aid of grants from ANPCyT, CONICET and SECyT UNC; and the European Union FP7 Health Research Grant No. FP7-HEALTH-F4-2008-202047-RESOLVE.

#### References

- Adam JA (1986) A simplified mathematical model of tumor growth. Math Biosci 81(2):229-244
- Agnelli J, Barrea A, Turner C (2011) Tumor location and parameter estimation by thermography. Math Comput Model 53(7–8):1527–1534
- Audet C, Dennis J (2002) Analysis of generalized pattern searches. SIAM J Optimiz 13(3):889–903
- Bellomo N, Li N, Maini P (2008) On the foundations of cancer modelling: selected topics, speculations, and
   perspectives. Math Model Methods Appl Sci 18(4):593–646
- Bellouquid A, De Angelis E, Knopoff D (2013) From the modeling of the immune hallmarks of cancer to a
   black swan in biology. Math Model Methods Appl Sci 23(05):949–978
- Bergstrom M, Monazzam A, Razifar P, Ide S, Josephsson R, Langstrom B (2008) Modeling spheroid growth,
   PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922. J. Nucl. Med. 49(7):1204–
   1210
- Byrne H, Chaplain M (1997) Free boundary value problems associated with the growth and development of
   multicellular spheroids. Eur J Appl Math 8(06):639–658
- Byrne H, Drasdo D (2009) Individual-based and continuum models of growing cell populations: a comparison.
   J Math Biol 58:657–687
- Crank J (1984) Free and moving boundary problems. Oxford Science Publications, The Clarendon Press,
   Oxford University Press, New York
- Dolan E, Lewis R, Torczon V (2003) On the local convergence of pattern search. SIAM J Optimiz 14(2):567–
   583
- 412 Edelman LB, Eddy JA, Price ND (2010) In silico models of cancer. WIREs Syst Biol Med 2(4):438–459
- Ford DK, Yerganian G (1958) Observations on the chromosomes of Chinese hamster cells in tissue culture. J
   Natl Cancer Inst 21(2):393–425
- Freyer JP, Sutherland RM (1986) Regulation of growth saturation and development of necrosis in EMT6/Ro
   multicellular spheroids by the glucose and oxygen supply. Cancer Res 46(7):3504–3512
- 417 Greenspan H (1972) Models for the growth of a solid tumor by diffusion. Stud Appl Math 51(4):317–340
- Grillo A, Wittum G, Giaquinta G, Mićunović MV (2009) A multiscale analysis of growth and diffusion
   dynamics in biological materials. Int J Eng Sci 47(2):261–283
- 420 Hamilton G (1998) Multicellular spheroids as an in vitro tumor model. Cancer Lett 131(1):29–34
- Herrmann R, Fayad W, Schwarz S, Berndtsson M, Linder S (2008) Screening for compounds that induce
   apoptosis of cancer cells grown as multicellular spheroids. J Biomol Screen 13(1):1–8
- Hlatky L, Sachs RK, Alpen EL (1988) Joint oxygen-glucose deprivation as the cause of necrosis in a tumor
   analog. J Cell Physiol 134(2):167–178
- Hogea C, Davatzikos C, Biros G (2008) An image-driven parameter estimation problem for a reaction-diffusion
   glioma growth model with mass effects. J Math Biol 56(6):793–825
- 427 Kiran KL, Jayachandran D, Lakshminarayanan S (2009) Mathematical modelling of avascular tumour growth
   428 based on diffusion of nutrients and its validation. Can J Chem Eng 87(5):732–740
- Knopoff D, Fernández D, Torres G, Turner C (2013) Adjoint method for a tumor growth PDE-constrained
   optimization problem. Comput Math Appl 66(6):1104–1119
- Lowengrub J, Frieboes H, Jin F, Chuang Y, Li X, Macklin P, Wise S, Cristini V (2010) Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity 23:R1
- Martin GR, Jain RK (1994) Noninvasive measurement of interstitial pH profiles in normal and neoplastic
   tissue using fluorescence ratio imaging microscopy. Cancer Res 54(21):5670–5674
- Monazzam A, Josephsson R, Blomqvist C, Carlsson J, Langstrom B, Bergstrom M (2007) Application of the
   multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy
   in breast cancer. Breast Cancer Res 9(4):R45
- Oden JT, Prudencio EE, Hawkins-Daarud A (2013) Selection and assessment of phenomenological models of
   tumor growth. Math Model Methods Appl Sci 23(07):1309–1338
- Perthame B, Zubelli JP (2007) On the inverse problem for a size-structured population model. Inverse Probl
   23(3):1037–1052
- Preziosi L, Vitale G (2011) A multiphase model of tumor and tissue growth including cell adhesion and plastic
   reorganization. Math Model Methods Appl Sci 21(09):1901–1932



302

- Rejniak K, McCawley L (2010) Current trends in mathematical modeling of tumor-microenvironment inter-111 actions: a survey of tools and applications. Exp Biol Med 235(4):411-423 445
- 446 Roose T, Chapman S, Maini P (2007) Mathematical models of avascular cancer. SIAM Rev 49(2):179-208
- 447 Sano Y, Hoshino T, Barker M, Deen DF (1984) Response of 9L rat brain tumor multicellular spheroids to single and fractionated doses of 1.3-bis (2-chloroethyl)-1-nitrosourea. Cancer Res 44(2):571-576 448
  - Sutherland R (1988) Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240(4849):177-184
  - Taylor DL, Waggoner AS, Lanni F, Murphy RF, Birge RR (1986) Applications of fluorescence in the biomedical sciences. Alan R, Liss Inc, Technical Report
- 453 Torczon V (1997) On the convergence of pattern search algorithms. SIAM J Optimiz 7(1):1–25
- Tracqui P (2009) Biophysical models of tumour growth. Rep Prog Phys 72:056701 454
- van den Doel K, Ascher UM, Pai DK (2011) Source localization in electromyography using the inverse 455 potential problem. Inverse Probl 27(2):025008 456
- Venkataraman P (2009) Applied optimization with MATLAB programming. Wiley, London 457
- Ward J, King J (1997) Mathematical modelling of avascular-tumour growth. Math Med Biol 14(1):39-69 458
- 459 Ward JP, King JR (2003) Mathematical modelling of drug transport in tumour multicell spheroids and mono-460 layer cultures. Math Biosci 181(2):177-207
- 461 Wise S, Lowengrub J, Frieboes H, Cristini V (2008) Three-dimensional multispecies nonlinear tumor growth-I: model and numerical method. J Theor Biol 253(3):524-543 462
- Zubelli JP, Marabini R, Sorzano COS, Herman GT (2003) Three-dimensional reconstruction by chahine's 463
- method from electron microscopic projections corrupted by instrumental aberrations. Inverse Probl 464 19(4):933-949 465

🖻 Springer IDMM

💢 Journal: 40314 Article No.: 0259 🗌 TYPESET 🗌 DISK 🗌 LE 🗌 CP Disp.: 2015/7/16 Pages: 16 Layout: Small



### Author Query Form

#### Please ensure you fill out your response to the queries raised below and return this form along with your corrections

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the 'Author's response' area provided below

Query	Details required	Author's response
1.	As per the information provided by the	
	publisher, Fig. 3 will be black and white	
	in print; hence, please confirm whether	
	we can add "colour figure online" to the	
	caption.	